March 11, 2020 / 11:23 AM / a month ago

BRIEF-Cerecor Reports 2019 Results

March 11 (Reuters) - Cerecor Inc:

* CERECOR REPORTS 2019 RESULTS

* CERECOR INC - CERC-800S (CERC-801, CERC-802 AND CERC-803) ANTICIPATE INITIAL DATA READOUT FROM CDG-FIRST TRIAL WITHIN 1 HALF 2020

* CERECOR INC - CERC-002 (ANTI-LIGHT MAB) BEING DEVELOPED FOR PEDIATRIC-ONSET CROHN’S DISEASE EXPECTS INITIAL DATA READOUT 2 HALF 2020

* CERECOR INC - CERC-007 (ANTI-IL-18 MAB) BEING DEVELOPED FOR AUTO-INFLAMMATORY DISEASES (AOSD, MM) IS EXPECTING INITIAL DATA READOUT Q4 2020 TO Q1 2021

* CERECOR INC - CERC-006 (DUAL MTOR INHIBITOR) BEING DEVELOPED FOR COMPLEX LYMPHATIC MALFORMATIONS ANTICIPATES INITIAL DATA READOUT 1 HALF 2021

* CERECOR - AVOIDED FUTURE CASH OUTFLOWS BY ELIMINATING LONG-TERM DEBT AND CONTINGENT CONSIDERATION, AS A RESULT OF AYTU DIVESTITURE IN 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below